Olmesartan Medoxomil/Amlodipine Rafarm (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Amlodipine Rafarm, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination for oral use. It treats hypertension, often in adults who require more than one medication to reach blood pressure goals. GNH USA supplies Olmesartan Medoxomil/Amlodipine Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomil/Amlodipine Rafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/amlodipine is indicated for hypertension, a condition managed through vascular resistance and fluid balance pathways. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension in patients uncontrolled on monotherapy: provides additional blood pressure reduction when an ARB alone is insufficient. - Hypertension with concomitant edema risk: amlodipine’s vasodilatory effect counteracts fluid retention often seen with other antihypertensives. - Hypertension in elderly patients: offers effective blood pressure control with a tolerable side‑effect profile. - Hypertension with metabolic syndrome: assists in blood pressure management without adversely affecting glucose or lipid metabolism.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Peripheral edema: swelling of the ankles or feet. - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth and redness of the skin. - Fatigue: general feeling of tiredness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of the face, lips, tongue, or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzyme elevations. - Acute kidney injury: sudden reduction in kidney function. - Myocardial infarction: rare occurrence of heart attack. - Hyperkalemia: elevated potassium levels in the blood.

Before starting therapy, clinicians should evaluate patient history and monitor relevant parameters. - Renal impairment: assess kidney function and adjust dose if needed. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular status: monitor for hypotension, especially in volume‑depleted patients. - Pregnancy and lactation: contraindicated; avoid use during pregnancy. - Drug‑specific monitoring: regular blood pressure checks and periodic laboratory tests. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil/amlodipine may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: concurrent use with ACE inhibitors or other ARBs increases risk of kidney injury and hyperkalemia. - Strong CYP3A4 inhibitors: agents such as ketoconazole can raise amlodipine levels, leading to excessive hypotension. - Lithium: co‑administration may raise lithium concentrations and precipitate toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate antihypertensive effect and cause orthostatic hypotension.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response and affect renal function. - Simvastatin: amlodipine increases its plasma concentration; dose adjustment may be needed.